SynthesisCurrent neurology and neuroscience reports2018
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
Synthesis in Current neurology and neuroscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04057456 (Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury), which is not on this map. Cited by 71 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury
Who cites it
71 citing papers in PubMed, 4 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Overcoming the impact of physiologic tremors in ophthalmology.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Pooled it
- Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.The Cochrane database of systematic reviews · 2022Pooled it
- A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.Medical cannabis and cannabinoids · 2021Pooled it
- Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2020Pooled it
- Telehealth tDCS to reduce cannabis use: A pilot RCT in multiple sclerosis as a framework for generalized use.Drug and alcohol dependence · 2025Trial
- Liquisolids as a platform for the formulation of cannabis tablets.International journal of pharmaceutics: X · 2026Article
- Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis.Archives of physical medicine and rehabilitation · 2026Article
- Chronic Pain in Multiple Sclerosis: Mechanisms, Clinical Characteristics and Treatment Strategies.International journal of molecular sciences · 2026Review
- Sustained Reduction of Dystonic Tremor and Pain after Cannabis Oil Administration and Physiotherapy in Thalamic Ischemia: A One-Year Case Report.Current neuropharmacology · 2026Article
- The unmet need for cannabis use disorder treatment in multiple sclerosis: Insights from a nationwide pilot study.Multiple sclerosis and related disorders · 2025Article
- Motherhood and medicinal cannabis.Drug and alcohol review · 2025Article
- Recreational drugs repurposed for medicinal use-cannabis.CNS spectrums · 2025Review
- Evaluating Vaporized Cannabinoid Therapy in Multiple Sclerosis: Findings from a Prospective Single-Center Clinical Study.Journal of clinical medicine · 2025Article
- Evidence synthesis of medical cannabis research: current challenges and opportunities.European archives of psychiatry and clinical neuroscience · 2025Review
- Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits.European archives of psychiatry and clinical neuroscience · 2025Review
- Structural basis of THC analog activity at the Cannabinoid 1 receptor.Nature communications · 2025Article
- Comparative targeted lipidomics between serum and cerebrospinal fluid of multiple sclerosis patients shows sex and age-specific differences of endocannabinoids and glucocorticoids.Acta neuropathologica communications · 2024Article
- Structural basis of ΔResearch square · 2024Article
- Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis.CNS drugs · 2024Review
- Efficient Capture ofMolecules (Basel, Switzerland) · 2024Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPharmaceutical cannabinoids such as nabiximols, nabilone and dronabinol, and plant-based cannabinoids have been investigated for their therapeutic potential in treating multiple sclerosis (MS) symptoms. This review of reviews aimed to synthesise findings from high quality systematic reviews that examined the safety and effectiveness of cannabinoids in multiple sclerosis. We examined the outcomes of disability and disability progression, pain, spasticity, bladder function, tremor/ataxia, quality of life and adverse effects. RECENT
findingsWe identified 11 eligible systematic reviews providing data from 32 studies, including 10 moderate to high quality RCTs. Five reviews concluded that there was sufficient evidence that cannabinoids may be effective for symptoms of pain and/or spasticity in MS. Few reviews reported conclusions for other symptoms. Recent high quality reviews find cannabinoids may have modest effects in MS for pain or spasticity. Future research should include studies with non-cannabinoid comparators; this is an important gap in the evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.